Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma

Archivum Immunologiae et Therapiae Experimentalis

Volumn 61, Issue 2, 2013, Pages 165-174

  Lech Maranda, Ewa ^a,b,c   Bienvenu, Jacques ^a,d   Broussais Guillaumot, Florence ^d   Michallet, Anne Sophie ^d   Warzocha, Krzysztof ^b   Biliński, Przemysław ^b,e   Boyle, Peter ^f   Coiffier, Bertrand ^a,d   Salles, Gilles ^a,d  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e Chief Sanitary Inspectorate   (Poland)

^f INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Chemotherapy; Diffuse large B cell lymphoma; Prognosis; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

ANTHRACYCLINES; B-LYMPHOCYTES; BIOMARKERS, PHARMACOLOGICAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879464150     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-012-0215-9     Document Type: Article

References (36)

1. Banks RE, Forbes MA, Kinsey SE et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956-964 (Pubitemid 28101786)
2. Bellamy WT, Richter L, Frutiger Y et al (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733 (Pubitemid 29076074)
3. Bertolini F, Paolucci M, Peccatori F et al (1999) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 106:504-509 (Pubitemid 29450678)
4. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253 (Pubitemid 29162950)
5. Coiffier B, Gisselbrecht C, Herbrecht R et al (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026 (Pubitemid 19196524)
6. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242 (Pubitemid 34438862)
7. Dvorak HF, Brown LF, Detmar M et al (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039
8. Etto L, Lacerda E, Baiocchi O et al (2008) Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma 49:257-264 (Pubitemid 351193917)
9. Gabrilovich D, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096-1103 (Pubitemid 26338628)
10. Ganjoo KN, An CS, Robertson MJ et al (2006) Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 47:998-1005 (Pubitemid 44102960)
11. Gerber HP, Malik AK, Solar GP et al (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417:954-958 (Pubitemid 34716872)
12. Giatromanolaki A, Koukourakis MI, Pezzella F et al (2008a) Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leuk Lymphoma 49:2181-2186
13. Giatromanolaki A, Koukourakis MI, Pezzella F et al (2008b) Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 26:219-224
14. Gratzinger D, Zhao S, Marinelli RJ et al (2007) Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 170:1362-1369 (Pubitemid 47339342)
15. Gratzinger D, Zhao S, Tibshirani RJ et al (2008) Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 88:38-47
16. Gratzinger D, Advani R, Zhao S et al (2010) Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survivalin diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol 148:235-244
17. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364 (Pubitemid 26272076)
18. Hazar B, Paydas S, Zorludemir S et al (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 44:2089-2093 (Pubitemid 37369649)
19. Koster A, Raemaekers JM (2005) Angiogenesis in malignant lymphoma. Curr Opin Oncol 17:611-616 (Pubitemid 41566417)
20. Labidi SI, Ménétrier-Caux C, Chabaud S et al (2010) Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival. Ann Hematol 89:25-33
21. Masood R, Cai J, Zheng T et al (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913
22. Negaard HF, Iversen N, Bowitz-Lothe IM et al (2009) Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 23:162-169
23. Niitsu N, Okamato M, Nakamine H et al (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 68:91-100 (Pubitemid 34478273)
24. Paydas S, Seydaoglu G, Ergin M et al (2009) The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma 50:366-373
25. Pedersen LM, Klausen TW, Davidsen UH et al (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 84:510-516 (Pubitemid 41001461)
26. Pfreundschuh M, Trümper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
27. Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105:1383-1395 (Pubitemid 40223651)
28. Roberts DM, Kearney JB, Johnson JH et al (2004) The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol 164:1531-1535 (Pubitemid 38529755)
29. Salven P, Teerenhovi L, Joensuu H (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90:3167-3172 (Pubitemid 27444212)
30. Salven P, Orpana A, Joensuu H (1999) Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5:487-491 (Pubitemid 29131955)
31. Salven P, Orpana A, Teerenhovi L et al (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96:3712-3718
32. Stopeck AT, Unger JM, Rimsza LM et al (2009) A phase II trial of single agent bevacizumab in patientswith relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 50:728-735
33. Vacca A, Ribatti D, Ruco L et al (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 79:965-970 (Pubitemid 29082134)
34. Wang ES, Teruya-Feldstein J, Wu Y et al (2004) Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 104:2893-2902 (Pubitemid 39434977)
35. Wosztyl A, Wolowiec D, Ziolkowska E et al (2012) Plasma concentration of cytokines involved in lympho- and angiogenesis in diffuse large B-cell lymphoma. Acta Haematol Pol 43:277-284
36. Wróbel T, Mazur G, Usnarska-Zubkiewicz L et al (2004) Vascular endothelial growth factor (VEGF) serum concentration in non Hodgkin's lymphoma patients. Pol Arch Med Wewn 112:919-923 (Pubitemid 39331164)